Tradestie Institutional Equity Comparison Engine

CLSD vs EKSO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-05-04 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EKSO Overall Edge

EKSO Captures Institutional Edge (2โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ekso Bionics Holdings, Inc. Common Stock (EKSO) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, CLSD trades at N/M Forward P/E with -3502.5% operating margin (-80.6% YoY revenue) versus EKSO at N/M Forward P/E and -119.7% operating margin (-38.3% YoY). In options structure, CLSD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against EKSO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CLSD N/M vs EKSO N/M Fwd P/E
Growth & Margin Winner EKSO
Op Margin -3502.5% vs -119.7% ยท YoY -80.6% vs -38.3%
Momentum & Technical Winner EKSO
1Y -97.5% vs +62.6% ยท 52W Pos 1% vs 87%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLSD NASDAQ
Clearside Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$0.41
-26.96% 1D
Market Cap $2.9M
1M Return -88.86%
1Y Return -97.47%
Forward P/E N/M
Unified AI Score
43.3 / 100 HOLD
Tech 40.0 Fund 43.0 Flow 50.0 Mom 40.0
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
1M Return +25.53%
1Y Return +62.6%
Forward P/E N/M
Unified AI Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLSD -97.47% EKSO +62.6% Spread: +61.97 pp (EKSO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLSD TTM Op. Margin: -3502.5% EKSO TTM Op. Margin: -119.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLSD vs EKSO. Trailing 12-month operating profitability (CLSD -3502.5% vs EKSO -119.7%) and valuation multiples (CLSD N/M vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLSD (1) vs EKSO (7)
Institutional Metric CLSD EKSO Criterion Row Winner
Market Capitalization Scale $2.9M $42.0M Larger Scale EKSO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -80.6% -38.3% Higher Growth EKSO
Operating Margin (TTM) Profitability -3502.5% -119.7% Higher Margin EKSO
Net Profit Margin Profitability 0.0% -91.4% Higher Margin CLSD
Return on Equity (ROE) Capital Efficiency -1310.0% -107.6% Higher ROE EKSO
52-Week Range Position Momentum 1% ($0โ€“$17) 87% ($0โ€“$14) Stronger Trend EKSO
Beta / 30D Volatility Risk Regime 2.24ฮฒ ยท 269% Vol 2.16ฮฒ ยท 76% Vol Lower Realized Risk EKSO
Unified Institutional Score Composite Signal 43.3 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite EKSO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLSD vs EKSO Buy Guide
CLSD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLSD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EKSO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EKSO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLSD nor EKSO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.